Skip to main content
Year archive

Vicore Pharma Holding — 2020 filings

All 40 regulatory filings released by Vicore Pharma Holding (VICO) in 2020, sourced directly from the official regulator.

40 Filings
2020 Period
2020 filings (40)
Filing Released Lang
Positive results show that C21 can become an important complement to COVID-19 vaccines
Earnings Release FY 2020
2020-12-21 English
Positiva resultat visar att C21 kan bli ett viktigt komplement till vacciner mot COVID-19
Regulatory Filings
2020-12-21 Swedish
Vicore Pharma rapporterar positiva resultat från ATTRACT-studien i patienter med COVID-19
Earnings Release FY 2020
2020-12-08 Swedish
Vicore Pharma reports positive top line data from the ATTRACT clinical study in patients with COVID-19
Earnings Release FY 2020
2020-12-08 English
Delårsrapport juli-september 2020
Interim / Quarterly Report 9M 2020
2020-11-06 Swedish
Interim report July-September 2020
Interim / Quarterly Report Q3 2020
2020-11-06 English
Vicore announces changes in management team
Board/Management Information
2020-11-03 English
Vicore meddelar förändringar i ledningsgruppen
Board/Management Information
2020-11-03 Swedish
Vicore strengthens its pipeline with the acquisition of novel AT2R agonists and decides on an issue in kind of 142,054 shares
Share Issue/Capital Change
2020-11-02 English
Vicore stärker sin pipeline genom förvärv av nya AT2R agonister och beslutar om en apportemission om 142 054 aktier
Share Issue/Capital Change
2020-11-02 Swedish
Vicore Pharma offentliggör valberedningen inför årsstämman 2021
AGM Information
2020-10-06 Swedish
Vicore Pharma announces the Nomination Committee for the 2021 Annual General Meeting
Board/Management Information
2020-10-06 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-31 English
Ökning av antalet aktier och röster i Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements
2020-08-31 Swedish
Increase of number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements
2020-08-31 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q2 2020
2020-08-26 Swedish
Interim report April-June 2020
Interim / Quarterly Report Q2 2020
2020-08-26 English
Delårsrapport april-juni 2020
Interim / Quarterly Report Q2 2020
2020-08-26 Swedish
Major Shareholding Notification 2020
Major Shareholding Notification
2020-08-19 Swedish
Vicore Pharma publishes a prospectus for admission to trading of shares on Nasdaq Stockholm in connection with a directed share issue
Share Issue/Capital Change
2020-08-13 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-08 English
Major Shareholding Notification 2020
Major Shareholding Notification
2020-07-06 English
Vicore Pharma har genomfört en riktad nyemission av aktier om 185 miljoner kronor
Capital/Financing Update
2020-07-03 Swedish
Vicore Pharma has completed a directed share issue of SEK 185 million
Share Issue/Capital Change
2020-07-03 English
Vicore Pharma avser att genomföra en riktad nyemission av aktier
Capital/Financing Update
2020-07-02 Swedish
Vicore Pharma intends to carry out a directed share issue
Capital/Financing Update
2020-07-02 English
Kommuniké från årsstämma i Vicore Pharma Holding AB (publ)
AGM Information
2020-05-20 Swedish
Bulletin from the Annual General Meeting of Vicore Pharma Holding AB (publ)
AGM Information
2020-05-20 English
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-05 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Q1 2020
2020-05-05 English
Kallelse till årsstämma i Vicore Pharma Holding AB (publ)
AGM Information
2020-04-17 Swedish
Notice of annual general meeting of Vicore Pharma Holding AB (publ)
AGM Information
2020-04-17 English
Annual Report 2019
Annual Report FY 2019
2020-04-15 Swedish
Annual Report 2019
Annual Report FY 2019
2020-04-15 English
Vicore Pharma, lämnar in ett ”Letter of Intent” gällande en myndighetsansökan för fas II-studie i patienter med COVID-19, SARS CoV-2-infektion
Regulatory Filings
2020-03-31 Swedish
Vicore Pharma submits Letter of Intent for a clinical trial application for a phase II study in patients with COVID-19, SARS CoV-2 infection
Regulatory Filings
2020-03-31 English
Earnings Release 2019
Earnings Release Q4 2019
2020-02-28 Swedish
Audit Report / Information 2019
Audit Report / Information FY 2019
2020-02-28 English
Ökning av antalet aktier och röster i Vicore Pharma
Share Issue/Capital Change
2020-01-31 Swedish
Increase of number of shares and votes in Vicore Pharma
Declaration of Voting Results & Voting Rights Announcements
2020-01-31 English